Melatonin as adjunctive therapy in patients admitted to the Covid-19

Karimpour-Razkenari, Elahe; Naderi-Behdani, Fahimeh; Salahshoor, Ali; Heydari, Fatemeh; Alipour, Abbas; Baradari, Afshin Gholipour

doi:10.1016/j.amsu.2022.103492

Cited by 3 publications

(3 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Figure 12. Random effects meta-analysis for all RCTs about melatonin in COVID-19 [133][134][135][136][137][138][139][140][141][142][143][144][145][146]. This plot shows pooled effects, see the specific outcome analyses for individual outcomes, and the heterogeneity section [21] for discussion.…”

Section: Melatoninmentioning

confidence: 99%

Neglected Effective Early Therapies against COVID-19: Focus on Functional Foods and Related Active Substances. A Review

Donzelli

2023

Preprint

View full text Add to dashboard Cite

The official recommendations to manage COVID-19 in the outpatient setting focus on high-cost drugs (remdesivir, nirmatrelvir-ritonavir, molnupiravir), suffering from many problems. Therefore, one may consider also other treatments meeting these criteria: • promising effectiveness, based on favorable randomized controlled trials (RCTs) of sufficient validity. Even without definitive evidence, physicians and informed patients can consider them if they are also: • safe, to the state of knowledge • with a very favorable opportunity cost • biologically plausible/not implausible • accessible • without major commercial sponsors in the trials promoting them, and with researchers without major conflicts of interests. The main focus is on a limited group of functional foods and some their active ingredients, with further mention of other substances of different origin, yet fully meeting all the aforementioned criteria. The functional foods and substances described and discussed certainly do not cover all the known effective therapies for COVID-19 (in one case also for Long-COVID), but the only therapies proposed in this paper currently satisfy all the above criteria. The supporting scientific evidence will favor meta-analyses of RCTs that include the most definitive outcome: all-cause mortality, i.e. the outcome that most fully informed people tend to prioritize. Furthermore, the reported evidence favors clinical studies of the most valid design, i.e. RCTs.

show abstract

Section: Melatoninmentioning

confidence: 99%

Neglected Effective Early Therapies against COVID-19: Focus on Functional Foods and Related Active Substances. A Review

Donzelli

2023

Preprint

View full text Add to dashboard Cite

show abstract

“…Melatonin can be a therapeutic option for treating cardiovascular disease. Melatonin inhibits the propagation of smooth myocytes in the pulmonary arteries and decreases the MAPK1/3 (ERK1/2) expression and phosphorylation of AKT (20).…”

Section: Cardiovascular Diseasementioning

confidence: 99%

“…A bioinformatic study by Yang et al explained the possible pharmacological mechanisms in treating diminished ovarian reserve by melatonin (19). Melatonin activates antioxidant enzymes at the mRNA level and increases anti-inflammatory activity and immune function (20). It reduces the risk of oxidative stress and cancer and is also responsible for modulating the neuroendocrine reproductive axis (21,22).…”

Section: Introductionmentioning

confidence: 99%

Therapeutic Target Analysis and Molecular Mechanism of Melatonin - Treated Leptin Resistance Induced Obesity: A Systematic Study of Network Pharmacology

Suriagandhi

Nachiappan

2022

Front. Endocrinol.

View full text Add to dashboard Cite

BackgroundObesity is a medical problem with an increased risk for other metabolic disorders like diabetes, heart problem, arthritis, etc. Leptin is an adipose tissue-derived hormone responsible for food intake, energy expenditure, etc., and leptin resistance is one of the significant causes of obesity. Excess leptin secretion by poor diet habits and impaired hypothalamic leptin signaling leads to LR. Melatonin a sleep hormone; also possess antioxidant and anti-inflammatory properties. The melatonin can attenuate the complications of obesity by regulating its targets towards LR induced obesity.AimThe aim of this study includes molecular pathway and network analysis by using a systems pharmacology approach to identify a potential therapeutic mechanism of melatonin on leptin resistance-induced obesity.MethodsThe bioinformatic methods are used to find therapeutic targets of melatonin in the treatment of leptin resistance-induced obesity. It includes target gene identification using public databases, Gene ontology, and KEGG pathway enrichment by ‘ClusterProfiler’ using the R language, network analysis by Cytoscape, and molecular Docking by Autodock.ResultsWe obtained the common top 33 potential therapeutic targets of melatonin and LR-induced obesity from the total melatonin targets 254 and common LR obesity targets 212 using the data screening method. They are involved in biological processes related to sleep and obesity, including the cellular response to external stimulus, chemical stress, and autophagy. From a total of 180 enriched pathways, we took the top ten pathways for further analysis, including lipid and atherosclerosis, endocrine, and AGE-RAGE signaling pathway in diabetic complications. The top 10 pathways interacted with the common 33 genes and created two functional modules. Using Cytoscape network analysis, the top ten hub genes (TP53, AKT1, MAPK3, PTGS2, TNF, IL6, MAPK1, ERBB2, IL1B, MTOR) were identified by the MCC algorithm of the CytoHubba plugin. From a wide range of pathway classes, melatonin can reduce LR-induced obesity risks by regulating the major six classes. It includes signal transduction, endocrine system, endocrine and metabolic disease, environmental adaptation, drug resistance antineoplastic, and cardiovascular disease.ConclusionThe pharmacological mechanism of action in this study shows the ten therapeutic targets of melatonin in LR-induced obesity.

show abstract